Spravato® (esketamine) is a prescription medication that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of treatment-resistant depression in adults. It is the first and only nasal spray form of ketamine, a fast-acting anesthetic that has been used for decades in medical settings.

Spravato® is administered by a healthcare provider in a certified medical office and is typically used in conjunction with an oral antidepressant medication. It works to restore brain connections that have been disrupted in those suffering from depression, and can provide rapid symptom relief in as little as 24 hours.

Many people with depression struggle with debilitating symptoms for weeks or even months before finding relief from traditional antidepressants. In clinical trials, Spravato has been shown to significantly reduce symptoms of depression in a shorter timeframe than oral antidepressants alone.

If you have tried multiple antidepressant medications without finding relief, Spravato may be an option for you. It has been shown to be effective in people who have not responded to at least two other antidepressant treatments.

If you are struggling with treatment-resistant depression and are looking for a new treatment option, reach out to learn more about the potential benefits of Spravato®.